BRIEF-Five Prime Therapeutics Starts Patient Dosing In Phase 1 Trial In Antibody Study
March 28, 2018 at 16:45 PM EDT
* FIVE PRIME THERAPEUTICS INITIATES PATIENT DOSING IN PHASE 1 TRIAL OF NOVEL FIRST-IN-CLASS B7-H4 ANTIBODY FPA150 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
